An Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism Who Completed the 12-Week Treatment Period in the Phase 2 Study, MBX-2H1002 Study (Avail-Ext)

Status: Active_not_recruiting

Location: See all (23) locations...

Intervention Type: Drug

Study Type: Interventional

Study Phase: Phase 2

SUMMARY

The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.

Eligibility

Participation Requirements

Sex: All

Minimum Age: 18

Maximum Age: 100

Healthy Volunteers: f

View:

• Must have completed the Week 12 Visit in MBX-2H1002 Study.

• Is an adult ≥18 years of age at the time of the Screening visit of this extension study.

• Has a diagnosis of one of the following types of hypoparathyroidism for at least 26 weeks prior to the

• Screening visit:

⁃ Postsurgical chronic hypoparathyroidism

⁃ Idiopathic hypoparathyroidism

⁃ Autoimmune hypoparathyroidism

• Can comprehend and is willing to sign an informed consent form (ICF), and abide by the study restrictions, study visits, and procedures.

• In the opinion of the investigator, must be able to successfully demonstrate reconstitution and self-administration of study drug.

Locations

United States

Florida